MCL Literature Feed

A machine learning algorithm accurately classifies MCL versus other B-cell lymphomas using standard peripheral blood flow cytometry data, offering a tool to standardize and accelerate initial diagnosis.

Italian real-world data highlights the poor prognosis and significant unmet clinical needs for relapsed/refractory MCL patients following covalent BTKi failure, emphasizing the urgency for novel treatment strategies.

This dual-center retrospective analysis of 20 patients with blastoid MCL characterizes its clinical features and prognosis, adding to the limited evidence base for this aggressive subtype.

The novel antiviral ensitrelvir resolved persistent COVID-19 in a heavily pretreated MCL patient on ibrutinib, highlighting a potential strategy to manage infections that delay essential lymphoma therapy.

An MCL patient with B-cell depletion had persistent COVID-19 for over 112 days, diagnosed via lower respiratory sampling, highlighting a unique vulnerability and successful treatment with convalescent plasma.

A preclinical prostate cancer model shows Bortezomib resistance is driven by autophagy induction and reduced oxidative stress, suggesting potential combination strategies with autophagy inhibitors for MCL.

This case of blastoid MCL with aberrant CD10 expression highlights a rare immunophenotype, creating a diagnostic pitfall that can mimic other aggressive B-cell lymphomas.

This paper outlines strategies for improved collaboration between community oncologists and authorized centers to overcome logistical and educational barriers, ensuring timely referral and access to CAR-T therapy for MCL.

This review explores targeting tumor-associated macrophages within the MCL microenvironment as a novel immunotherapeutic strategy to enhance anti-tumor activity and potentially overcome drug resistance.

This retrospective study outlines real-world treatment patterns for MCL from a single private practice in Brazil, providing crucial data on management outside of traditional clinical trial or academic settings.

This review identifies the lncRNA LINK-A as an upregulated oncogene in MCL, presenting it as a potential biomarker and therapeutic target involved in oncogenic pathways and therapy resistance.

A novel SRC-3 inhibitor, SI-10, demonstrates preclinical efficacy in ibrutinib-resistant MCL models, identifying SRC-3 as a potential therapeutic target to overcome BTKi resistance.

This systematic review of real-world data supports positioning covalent BTKis as second-line therapy for relapsed/refractory MCL, followed by CAR-T cells for patients relapsing after BTKi treatment.

This retrospective review of 14 Moroccan patients describes real-world MCL clinical features and treatment patterns, providing rare epidemiological data from North Africa.

This review details the pathophysiology and management of CAR-T toxicities like CRS and ICANS, providing essential guidance for clinicians treating relapsed/refractory MCL patients with this therapy.

This review identifies the lncRNA ROR1-AS1 as a pro-oncogenic factor in mantle cell lymphoma, suggesting it may serve as a novel biomarker or therapeutic target.

This Mendelian randomization study suggests potential causal links between socioeconomic factors and lymphoma development, which may help define modifiable risk factors relevant to MCL etiology.

This case report describes a rare transformation of CD5-negative MCL into an EBV-positive pleomorphic variant, highlighting a potential role for EBV in aggressive disease progression and diagnosis.

In a large retrospective series of bilateral lacrimal gland lesions, mantle cell lymphoma was identified as a rare cause (4.4%), highlighting an uncommon extranodal presentation for clinicians.

This preclinical study identifies a novel STAT5B-DCAF13-p53/xCT pathway that suppresses ferroptosis to promote MCL progression, revealing ferroptosis induction as a potential new therapeutic strategy.

A rare case of extranodal composite MCL and classical Hodgkin lymphoma highlights the need for comprehensive pathological workup to identify dual pathologies, which impacts treatment and relapse patterns.

This review consolidates efficacy and toxicity data for FDA-approved CAR-T products in aggressive B-cell lymphomas, including MCL, serving as a practical guide for this established relapsed/refractory treatment.

This case of asymptomatic multiple lymphomatous polyposis in an elderly MCL patient demonstrates that significant GI involvement can be clinically silent, reinforcing the need for routine endoscopic staging.

This single-center retrospective study characterizes the aggressive clinical and pathological features of blastoid MCL, underscoring its diagnostic challenges and the need for novel therapeutic approaches for this high-risk subtype.

This case of lacrimal sac MCL, initially misdiagnosed as a mucocele, highlights a rare extranodal presentation requiring histopathological confirmation for accurate diagnosis in atypical periorbital masses.

Magnetic Resonance Spectroscopy (MRS) can non-invasively detect metabolic changes, like lactate and alanine, offering an early biomarker to predict response or resistance to BTK inhibitors in MCL.

This meta-analysis of 984 R/R MCL patients confirms high CAR-T efficacy (74% CR, 69% 1-year OS), providing robust, pooled outcome data for this heavily pretreated population.

This review summarizes the evolving Japanese MCL treatment landscape, highlighting novel therapies like BTKi, BCL2i, and CAR-T to address resistance in high-risk subsets like TP53-mutated and blastoid.

This indirect comparison shows acalabrutinib has a superior safety profile to ibrutinib in relapsed/refractory MCL with similar efficacy, supporting its preferential use in this setting.

This case report identifies therapy-related acute myeloid leukemia as a serious long-term toxicity after brexucabtagene autoleucel, highlighting the need for post-CAR-T surveillance for secondary malignancies.